BPC-157
Tissue and Repair Signalling
£28.00per vial
BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of Body Protection Compound, a protein identified in human gastric juice. Preclinical literature examines it in tissue-repair and gastrointestinal models, with attention to angiogenic signalling, nitric-oxide pathways, and fibroblast migration. Human data are limited.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
BPC-157 cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 1419.5 g/mol
- Sequence
- GEPPPGKPADDAGLV
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for BPC-157, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 1419.5 g/mol
- Sequence
- GEPPPGKPADDAGLV
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- BP5601
Molecular weight source: PubChem CID 9941957.
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 98.6% |
| Identity | Mass spectrometry | Confirmed |
BP5601 · 2026-05-12
§04Compound details
BPC-157 is a stable 15-amino-acid peptide derived from a partial sequence of a protein isolated from human gastric juice. In controlled laboratory settings it is studied for its interaction with angiogenic signalling, principally VEGFR2 pathway activity, and for its modulation of nitric-oxide synthesis. Its resistance to degradation in gastric acid is one of the structural characteristics that keeps it in circulation as a research compound.
Preclinical investigations have examined BPC-157 in fibroblast migration assays, growth-factor expression models, and cytoprotective pathway analysis. Published work references FAK-paxillin signalling, EGR-1 expression, and early-response gene activity as the mechanisms under examination. Research models span tendon, ligament, and gastrointestinal mucosal frameworks, and the compound is also examined in vascular and neurovascular signalling contexts.
BPC-157 is catalogued here as a reference compound for laboratory research. Published findings are drawn overwhelmingly from animal and cell-culture models. Controlled human data remain limited and are contested in the literature. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
BPC-157 is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number. That batch number resolves to the public Certificate of Analysis for that batch, which reports the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue, not issued on request afterwards.
Research Use Only
BPC-157 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about BPC-157. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for BPC-157 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
BPC-157 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
BPC-157 is a stable 15-amino-acid peptide derived from a partial sequence of a protein isolated from human gastric juice. In controlled laboratory settings it is studied for its interaction with angiogenic signalling, principally VEGFR2 pathway activity, and for its modulation of nitric-oxide synthesis. Its resistance to degradation in gastric acid is one of the structural characteristics that keeps it in circulation as a research compound.
Preclinical investigations have examined BPC-157 in fibroblast migration assays, growth-factor expression models, and cytoprotective pathway analysis. Published work references FAK-paxillin signalling, EGR-1 expression, and early-response gene activity as the mechanisms under examination. Research models span tendon, ligament, and gastrointestinal mucosal frameworks, and the compound is also examined in vascular and neurovascular signalling contexts.
BPC-157 is catalogued here as a reference compound for laboratory research. Published findings are drawn overwhelmingly from animal and cell-culture models. Controlled human data remain limited and are contested in the literature. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
BPC-157 is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number. That batch number resolves to the public Certificate of Analysis for that batch, which reports the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue, not issued on request afterwards.
Compliance Notice
Research Use Only
BPC-157 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about BPC-157. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for BPC-157 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
BPC-157 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. BPC-157 is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Angiogenic signalling, nitric-oxide pathway modulation, and cellular migration in laboratory tissue-repair and gastrointestinal models. Findings are preclinical.
Body Protection Compound-157. It is a synthetic pentadecapeptide corresponding to a partial sequence of a protein identified in human gastric juice.
Pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised powder and needs no preparation before laboratory use.
HPLC for purity and mass spectrometry for identity, on every batch, before it is listed. Those two methods are the full analytical panel and no further assay is claimed.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
